NERVGEN PHARMA CORP (NGEN.CA) Forecast, Price Target & Analyst Ratings

TSX-V:NGEN • CA64082X2032

Current stock price

5.15 CAD
+0.15 (+3%)
Last:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for NERVGEN PHARMA CORP (NGEN.CA).

Forecast Snapshot

Consensus Price Target

Price Target
CA$7.75
+ 50.52% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
Apr 2, 2026
Period
Q4 / 2025
EPS Estimate
-CA$0.10
Revenue Estimate
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
80.00%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
CA$7.75
Upside
+ 50.52%
From current price of CA$5.15 to mean target of CA$7.75, Based on 8 analyst forecasts
Low
CA$5.05
Median
CA$8.01
High
CA$10.19

Price Target Revisions

1 Month
0.00%
3 Months
7.04%

Price Target Summary

8 Wall Street analysts provided a forecast for the next 12 months for NGEN.CA. The average price target is 7.75 CAD. This implies a price increase of 50.52% is expected in the next year compared to the current price of 5.15.
The average price target has been revised upward by 7.04% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

NGEN Current Analyst RatingNGEN Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 1 2 3 4 5

Analyst Ratings History

NGEN Historical Analyst RatingsNGEN Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6

Analyst Ratings Consensus

ChartMill Buy Consensus
80.00%
NGEN.CA was analyzed by 8 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about NGEN.CA.
In the previous month the buy percentage consensus was at a similar level.
NGEN.CA was analyzed by 8 analysts. More opinions would make the average more meaningful.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

Next Earnings Forecast Details

Next Earnings Details

Release Date
Apr 2, 2026
Period
Q4 / 2025
EPS Estimate
-CA$0.10
Revenue Estimate
Revenue Q2Q
N/A
EPS Q2Q
26.19%
Number of Analysts
3

Next Earnings Revisions

Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
-58.33%
EPS (3 Months)
-58.33%

Next Earnings Summary

NGEN.CA is expected to report earnings on 4/2/2026. The consensus EPS estimate for the next earnings is -0.1 CAD and the consensus revenue estimate is 0 CAD.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2025 - 2033

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
NGEN.CA revenue by date.NGEN.CA revenue by date.
N/AN/AN/AN/AN/A
3,537.93%		N/A
64.84%		N/A
49.90%		N/A
27.33%		N/A
23.70%
EBITDA
YoY % growth
NGEN.CA ebitda by date.NGEN.CA ebitda by date.
-11.8K-1.339M
-11,244.92%		-9.826M
-634.01%		-11.156M
-13.54%		-12.769M
-14.45%		-23.425M
-83.45%		-17.632M
24.73%		-24.848M
-40.93%		N/A
10.58%		N/AN/AN/AN/AN/AN/AN/AN/A
EBIT
YoY % growth
NGEN.CA ebit by date.NGEN.CA ebit by date.
-11.8K-1.359M
-11,412.71%		-9.864M
-626.12%		-11.196M
-13.50%		-12.811M
-14.43%		-23.54M
-83.74%		-17.777M
24.48%		-24.932M
-40.25%		N/A
-206.29%		N/A
-2.70%		N/A
130.26%		N/A
1,391.32%		N/A
33.23%		N/A
49.77%		N/A
39.19%		N/A
29.09%		N/A
24.98%
Operating Margin
NGEN.CA operating margin by date.NGEN.CA operating margin by date.
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
EPS
YoY % growth
NGEN.CA eps by date.NGEN.CA eps by date.
N/AN/AN/AN/AN/A-0.42
-34.14%		N/A
25.45%		-0.35
-11.79%		N/A
24.97%		N/A
-13.46%		N/A
15.25%		N/A
104.08%		N/A
19,376.47%		N/A
122.44%		N/AN/AN/A

All data in CAD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q4 / 25 Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26
EPS
Q2Q % growth		-0.10
26.19%		-0.05
15.83%		-0.05
61.15%		-0.05
15.83%		-0.05
47.37%
Revenue
Q2Q % growth
-100.00%
EBITDA
Q2Q % growth		-9.292M
-38.24%		N/AN/AN/AN/A
EBIT
Q2Q % growth		N/AN/AN/AN/AN/A

All data in CAD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

NGEN.CA Yearly Revenue VS EstimatesNGEN.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
NGEN.CA Yearly EPS VS EstimatesNGEN.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 2 3 4

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
8.54%
EPS Next 5 Year
50.55%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

NERVGEN PHARMA CORP / NGEN.CA Forecast FAQ

What is the average price target for NERVGEN PHARMA CORP (NGEN.CA) stock?

8 analysts have analysed NGEN.CA and the average price target is 7.75 CAD. This implies a price increase of 50.52% is expected in the next year compared to the current price of 5.15.

When does NERVGEN PHARMA CORP (NGEN.CA) report earnings?

NERVGEN PHARMA CORP (NGEN.CA) will report earnings on 2026-04-02.

What are the consensus estimates for NGEN stock next earnings?

The consensus EPS estimate for the next earnings of NERVGEN PHARMA CORP (NGEN.CA) is -0.1 CAD and the consensus revenue estimate is 0 CAD.

What is the consensus rating for NGEN stock?

The consensus rating for NERVGEN PHARMA CORP (NGEN.CA) is 80 / 100 . This indicates that analysts generally have a positive outlook on the stock.